Opportunistic invasive fungal pathogen Macrophomina phaseolina prognosis from immunocompromised humans to potential mitogenic RBL with an exceptional and novel antitumor and cytotoxic effect

• Published in: European journal of clinical microbiology & infectious diseases Vol. 31; no. 2; pp. 101 - 107
• Main Authors: Arora, P., Dilbaghi, N., Chaudhury, A.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.02.2012; Springer; Springer Nature B.V
• Subjects: Adult; Amino Acid Sequence; Animals; Antifungal agents; Antifungal Agents - pharmacology; Antifungal Agents - therapeutic use; Antineoplastic Agents - metabolism; Antineoplastic Agents - pharmacology; Antitumor activity; Ascomycota - classification; Ascomycota - drug effects; Ascomycota - pathogenicity; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Child; Cytotoxicity; Fungal infections; Fungi; Genetic Therapy - methods; Humans; Immunity; Immunocompromised Host; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Infection; Infectious diseases; Internal Medicine; Lectins; Lectins - genetics; Lectins - metabolism; Lectins - pharmacology; Macrophomina phaseolina; Male; Medical Microbiology; Medical sciences; Mitogens - pharmacology; Molecular Sequence Data; Mycoses - drug therapy; Mycoses - microbiology; Mycoses - therapy; Opportunist infection; Opportunistic Infections - drug therapy; Opportunistic Infections - microbiology; Opportunistic Infections - therapy; Pathogens; Patients; Prognosis; Prophylaxis; Review; Rhizoctonia - classification; Rhizoctonia - genetics; Rhizoctonia - metabolism; Rhizoctonia bataticola; Ribosomal DNA; Risk factors; Risk groups; Stem cells; Fungal Lectin; Internal Transcribe Spacer; Opportunistic Mycosis; Invasive Fungal Infection; Mitogenic Lectin; Fungi; Antineoplastic agent; Human; Immunopathology; Opportunistic infection; Prognosis; Microbiology; Macrophomina phaseolina; Fungi Imperfecti; Immune deficiency
• ISSN: 0934-9723; 1435-4373
• DOI: 10.1007/s10096-011-1275-1

With the ever-increasing risk for fungal infections, one can no longer ignore fungi. It is imperative that clinical manifestations “presume fungus” with their epidemiologic and pathogenic features when evaluating a potentially infected patient. In the high-risk patient groups, fungi with intrinsic resistance to antifungal agents already exist, with a tendency to emerge as opportunistic pathogens. One of the smart pathogens is Macrophomina phaseolina , with the potential to disarm plant, animal, and human immunity. The response prophylaxis may vary from antifungal therapy and surgical measures to biochemical ( Rhizoctonia bataticola lectin [RBL] with antitumor and cytotoxic nature) and gene therapeutics.